Ivan Moller - Zealand Pharma Chief Officer
Insider
Ivan Moller is Chief Officer of Zealand Pharma AS
| Age | 50 |
| Phone | 45 88 77 36 00 |
| Web | https://www.zealandpharma.com |
Zealand Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3786) % which means that it has lost $0.3786 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1545) %, meaning that it created substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Zealand Pharma AS currently holds 647.91 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Zealand Pharma AS has a current ratio of 4.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zealand Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ming Li | Alvotech | 47 | |
| M MD | Lipocine | 66 | |
| Joseph McClellan | Alvotech | 50 | |
| Sean Gaskell | Alvotech | 42 | |
| Barry Gordon | Diamond Estates Wines | N/A | |
| Mark Levick | Alvotech | 60 | |
| Michael Boehler | BioNTech SE | N/A | |
| John Hadgkiss | Vodka Brands Corp | 74 | |
| Logan Morse | Lipocine | 54 | |
| RoseMarie Ohlsson | Alvotech | N/A | |
| Jens Holstein | BioNTech SE | 61 | |
| Sierk Poetting | BioNTech SE | 51 | |
| Andrew Green | Diamond Estates Wines | 54 | |
| Krista Fogarty | Lipocine | 56 | |
| Ryan Conte | Diamond Estates Wines | N/A | |
| Joel Morales | Alvotech | 46 | |
| Mark Lucero | Vodka Brands Corp | 73 | |
| HDipTax HDipLaw | Monster Beverage Corp | 74 | |
| Ozlem MD | BioNTech SE | 57 | |
| Anil Okay | Alvotech | 38 | |
| Sigridur Gudlaugsdottir | Alvotech | N/A | |
Management Performance
| Return On Equity | -1.15 | |||
| Return On Asset | -0.38 |
Zealand Pharma AS Leadership Team
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lani Morvan, Investor Officer | ||
| Hanne Bak, Director, Employee Representative | ||
| Adam MD, Pres CEO | ||
| Mads Kronborg, Head Communication | ||
| Ravinder Chahil, Sr Counsel | ||
| Danilo Verge, Head Affairs | ||
| Christina Bredal, VP Organization | ||
| Ivan Moller, Chief Officer | ||
| Jens MD, Head Pharmacology | ||
| David MD, Chief Officer |
Zealand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.15 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 1.32 B | |||
| Shares Outstanding | 46.12 M | |||
| Shares Owned By Institutions | 1.74 % | |||
| Number Of Shares Shorted | 75.47 K | |||
| Price To Earning | 10.49 X | |||
| Price To Book | 9.54 X | |||
| Price To Sales | 2.77 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Zealand Stock
If you are still planning to invest in Zealand Pharma AS check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zealand Pharma's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |